Portal Hypertension and Liver Transplantation: Current Situation in Japan and Overseas

  • Junichi Kaneko
  • Norihiro KokudoEmail author


Liver transplantation is the only curative treatment option for both portal hypertension and end-stage liver disease (ESLD). In Japan, 50–60 deceased-donor liver transplant (DDLTs) and 400–500 living-donor liver transplant (LDLTs) are performed per year. Spain is the most DDLT-active country, and South Korea is the most LDLT-active country, performing 52 times as many and 5 times as many liver transplants per capita than Japan, respectively. Managing portal hypertension, ascites, hepatorenal syndrome, and spontaneous bacterial peritonitis is the key for bridging the interim period in patients waiting for liver transplantation. The Baveno VI consensus workshop recommendation is an important strategy for portal hypertension patients. International ascites club guidelines are other crucial strategies for ESLD patients. For a successful liver transplantation, multidisciplinary approach is essential to manage patients during both pre- and posttransplant periods. Regarding post-liver transplant patients, although liver transplantation resolves portal hypertension, a small-for-size graft in LDLT, acute rejection, and recurrence of the original liver disease may lead to newly developing or recurring portal hypertension. Further studies are needed to develop a management strategy for portal hypertension in pre- and post-liver transplant patients.


Baveno VI consensus International ascites club guideline Deceased-donor Living-donor Liver transplantation 


  1. 1.
    Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet. 1963;117:659–76.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Organ Procurement and Transplantation Network data. Accessed 18 July 2016.
  3. 3.
    Trotter JF, Cardenas A. Liver transplantation around the world. Liver Transpl. 2016;22(8):1059–61.CrossRefGoogle Scholar
  4. 4.
    Eurotransplant. Accessed 18 July 2016.
  5. 5.
    Wang H, Jiang W, Zhou Z, Long J, Li W, Fan ST. Liver transplantation in mainland China: the overview of CLTR 2011 annual scientific report. Hepatobiliary Surg Nutr. 2013;2(4):188–97.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Trey T, Halpern A, Singh MA. Organ transplantation and regulation in China. JAMA. 2011;306(17):1863–4; author reply 4.CrossRefGoogle Scholar
  7. 7.
    Strong RW, Lynch SV, Ong TH, Matsunami H, Koido Y, Balderson GA. Successful liver transplantation from a living donor to her son. N Engl J Med. 1990;322(21):1505–7.CrossRefGoogle Scholar
  8. 8.
    Raia S, Nery JR, Mies S. Liver transplantation from live donors. Lancet. 1989;2(8661):497.CrossRefGoogle Scholar
  9. 9.
    Nagasue N, Kohno H, Matsuo S, Yamanoi A, Uchida M, Takemoto Y, et al. Segmental (partial) liver transplantation from a living donor. Transplant Proc. 1992;24(5):1958–9.PubMedGoogle Scholar
  10. 10.
    Hashikura Y, Makuuchi M, Kawasaki S, Matsunami H, Ikegami T, Nakazawa Y, et al. Successful living-related partial liver transplantation to an adult patient. Lancet. 1994;343(8907):1233–4.CrossRefGoogle Scholar
  11. 11.
    Japan OrganTransplant Network. Accessed 18 July 2016.
  12. 12.
    Chen CL, Kabiling CS, Concejero AM. Why does living donor liver transplantation flourish in Asia? Nat Rev Gastroenterol Hepatol. 2013;10(12):746–51.CrossRefGoogle Scholar
  13. 13.
    Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–71.CrossRefGoogle Scholar
  14. 14.
    Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797–805.CrossRefGoogle Scholar
  15. 15.
    MELD and PELD Calculator by Organ Procurement and Transplantation Network. Accessed 18 July 2016.
  16. 16.
    Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant. 2005;5(2):307–13.CrossRefGoogle Scholar
  17. 17.
    Zaman A, Hapke R, Flora K, Rosen H, Benner K. Prevalence of upper and lower gastrointestinal tract findings in liver transplant candidates undergoing screening endoscopic evaluation. Am J Gastroenterol. 1999;94(4):895–9.CrossRefGoogle Scholar
  18. 18.
    Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46(3):922–38.CrossRefGoogle Scholar
  19. 19.
    Wedd J, Bambha KM, Stotts M, Laskey H, Colmenero J, Gralla J, et al. Stage of cirrhosis predicts the risk of liver-related death in patients with low model for end-stage liver disease scores and cirrhosis awaiting liver transplantation. Liver Transpl. 2014;20(10):1193–201.CrossRefGoogle Scholar
  20. 20.
    Cardenas A, Gines P. Management of patients with cirrhosis awaiting liver transplantation. Gut. 2011;60(3):412–21.CrossRefGoogle Scholar
  21. 21.
    de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–52.CrossRefGoogle Scholar
  22. 22.
    Centre for Evidence-Based Medicine. Accessed 10 Oct 2016.
  23. 23.
    Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64(4):531–7.CrossRefGoogle Scholar
  24. 24.
    Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310–8.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005;41(6):1282–9.CrossRefGoogle Scholar
  26. 26.
    European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397–417.CrossRefGoogle Scholar
  27. 27.
    Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130(6):1652–60.CrossRefGoogle Scholar
  28. 28.
    Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099–112.CrossRefGoogle Scholar
  29. 29.
    Samsca (tolvaptan): drug warning—potential risk of liver injury by U.S. Food and Drug Administration. Accessed 10 Oct 2016.
  30. 30.
    Cheng YF, Ou HY, Tsang LL, Yu CY, Huang TL, Chen TY, et al. Vascular stents in the management of portal venous complications in living donor liver transplantation. Am J Transplant. 2010;10(5):1276–83.CrossRefGoogle Scholar
  31. 31.
    Arab JP, Meneses L, Perez RM, Arrese M, Benitez C. Hepatic encephalopathy in a liver transplant recipient with stable liver function. Hepatology. 2013;57(4):1672–4.CrossRefGoogle Scholar
  32. 32.
    Herrero JI, Bilbao JI, Diaz ML, Alegre F, Inarrairaegui M, Pardo F, et al. Hepatic encephalopathy after liver transplantation in a patient with a normally functioning graft: treatment with embolization of portosystemic collaterals. Liver Transpl. 2009;15(1):111–4.CrossRefGoogle Scholar
  33. 33.
    Abe S, Akamatsu N, Hoshikawa M, Shirata C, Sakamoto Y, Hasegawa K, et al. Ectopic jejunal variceal rupture in a liver transplant recipient successfully treated with percutaneous transhepatic coil embolization: a case report. Medicine. 2015;94(47):e2151.CrossRefGoogle Scholar
  34. 34.
    Starzl TE. The long reach of liver transplantation. Nat Med. 2012;18(10):1489–92.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Hepato-Billiary-Pancreatic Surgery Division, Artificial Organ and Transplantation DivisionDepartment of Surgery, Graduate School of Medicine, The University of TokyoTokyoJapan
  2. 2.National Center for Global Health and MedicineTokyoJapan

Personalised recommendations